Does the media prefer BEAM or CADL?

In the previous week, Beam Therapeutics had 6 more articles in the media than Candel Therapeutics. MarketBeat recorded 13 mentions for Beam Therapeutics and 7 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of -0.08 beat Beam Therapeutics' score of -0.13 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation & earnings, KOD or CADL?

Kodiak Sciences is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is KOD or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Candel Therapeutics N/A -60.42% -41.33%

Does the media refer more to KOD or CADL?

In the previous week, Kodiak Sciences had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 8 mentions for Kodiak Sciences and 7 mentions for Candel Therapeutics. Kodiak Sciences' average media sentiment score of 0.57 beat Candel Therapeutics' score of -0.08 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is CADL or IMNM more profitable?

Immunome's return on equity of -51.15% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Immunome N/A -51.15% -47.32%

Does the media favor CADL or IMNM?

In the previous week, Candel Therapeutics had 3 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Candel Therapeutics and 4 mentions for Immunome. Immunome's average media sentiment score of 0.83 beat Candel Therapeutics' score of -0.08 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Immunome 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NRIX or CADL?

In the previous week, Nurix Therapeutics had 15 more articles in the media than Candel Therapeutics. MarketBeat recorded 22 mentions for Nurix Therapeutics and 7 mentions for Candel Therapeutics. Nurix Therapeutics' average media sentiment score of 0.21 beat Candel Therapeutics' score of -0.08 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Candel Therapeutics (CADL) Competitors

$10.59 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$10.58 -0.01 (-0.11%)

As of 08/7/2026 07:56 PM Eastern

Compare

CADL vs. BEAM, KOD, IMNM, RARE, and NRIX

Should you buy Candel Therapeutics stock or one of its competitors? MarketBeat compares Candel Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Candel Therapeutics include Beam Therapeutics (BEAM), Kodiak Sciences (KOD), Immunome (IMNM), Ultragenyx Pharmaceutical (RARE), and Nurix Therapeutics (NRIX). These companies are all part of the "biotechnology" industry.

How does Candel Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Candel Therapeutics (NASDAQ:CADL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Candel Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	20.31	-$79.99M	-$0.86	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

In the previous week, Beam Therapeutics had 6 more articles in the media than Candel Therapeutics. MarketBeat recorded 13 mentions for Beam Therapeutics and 7 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of -0.08 beat Beam Therapeutics' score of -0.13 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Beam Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, indicating that its stock price is 151% less volatile than the broader market.

Candel Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Candel Therapeutics	N/A	-60.42%	-41.33%

Beam Therapeutics presently has a consensus price target of $49.00, suggesting a potential upside of 78.31%. Candel Therapeutics has a consensus price target of $18.57, suggesting a potential upside of 75.37%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Beam Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Beam Therapeutics beats Candel Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Candel Therapeutics compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Candel Therapeutics (NASDAQ:CADL) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Kodiak Sciences has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, suggesting that its stock price is 151% less volatile than the broader market.

In the previous week, Kodiak Sciences had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 8 mentions for Kodiak Sciences and 7 mentions for Candel Therapeutics. Kodiak Sciences' average media sentiment score of 0.57 beat Candel Therapeutics' score of -0.08 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Kodiak Sciences is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Kodiak Sciences presently has a consensus price target of $48.14, suggesting a potential upside of 6.11%. Candel Therapeutics has a consensus price target of $18.57, suggesting a potential upside of 75.37%. Given Candel Therapeutics' higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Candel Therapeutics' return on equity of -60.42% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Candel Therapeutics	N/A	-60.42%	-41.33%

89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 44.4% of Kodiak Sciences shares are held by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Candel Therapeutics beats Kodiak Sciences on 7 of the 13 factors compared between the two stocks.

How does Candel Therapeutics compare to Immunome?

Candel Therapeutics (NASDAQ:CADL) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Immunome's return on equity of -51.15% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Immunome	N/A	-51.15%	-47.32%

Candel Therapeutics has higher earnings, but lower revenue than Immunome. Candel Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Immunome	$6.94M	408.45	-$212.39M	-$2.38	N/A

In the previous week, Candel Therapeutics had 3 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Candel Therapeutics and 4 mentions for Immunome. Immunome's average media sentiment score of 0.83 beat Candel Therapeutics' score of -0.08 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunome	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics has a beta of -0.51, indicating that its share price is 151% less volatile than the broader market. Comparatively, Immunome has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market.

Candel Therapeutics presently has a consensus target price of $18.57, indicating a potential upside of 75.37%. Immunome has a consensus target price of $34.18, indicating a potential upside of 36.56%. Given Candel Therapeutics' higher possible upside, analysts clearly believe Candel Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Immunome beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Candel Therapeutics compare to Ultragenyx Pharmaceutical?

Candel Therapeutics (NASDAQ:CADL) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Candel Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Candel Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Ultragenyx Pharmaceutical	$673M	3.80	-$575M	-$5.84	N/A

Candel Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Candel Therapeutics' return on equity of -60.42% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Candel Therapeutics has a beta of -0.51, suggesting that its share price is 151% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical had 17 more articles in the media than Candel Therapeutics. MarketBeat recorded 24 mentions for Ultragenyx Pharmaceutical and 7 mentions for Candel Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.30 beat Candel Therapeutics' score of -0.08 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	7 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Candel Therapeutics presently has a consensus price target of $18.57, indicating a potential upside of 75.37%. Ultragenyx Pharmaceutical has a consensus price target of $57.82, indicating a potential upside of 123.17%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Ultragenyx Pharmaceutical beats Candel Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Candel Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Candel Therapeutics (NASDAQ:CADL) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

13.9% of Candel Therapeutics shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Candel Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Candel Therapeutics' return on equity of -60.42% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Candel Therapeutics	N/A	-60.42%	-41.33%

In the previous week, Nurix Therapeutics had 15 more articles in the media than Candel Therapeutics. MarketBeat recorded 22 mentions for Nurix Therapeutics and 7 mentions for Candel Therapeutics. Nurix Therapeutics' average media sentiment score of 0.21 beat Candel Therapeutics' score of -0.08 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Nurix Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, indicating that its stock price is 151% less volatile than the broader market.

Candel Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	31.55	-$264.46M	-$3.45	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Nurix Therapeutics presently has a consensus target price of $34.00, indicating a potential upside of 33.18%. Candel Therapeutics has a consensus target price of $18.57, indicating a potential upside of 75.37%. Given Candel Therapeutics' higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Candel Therapeutics beats Nurix Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Candel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CADL vs. The Competition

Export

Metric	Candel Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$775.93M	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-10.81	9.02	270.59	25.05
Price / Sales	N/A	1,294.55	599.41	84.35
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	11.15	17.61	11.21	6.43
Net Income	-$38.18M	-$13.25M	$3.45B	$348.10M
7 Day Performance	5.16%	4.99%	3.41%	2.68%
1 Month Performance	11.59%	-2.13%	-0.71%	-0.83%
1 Year Performance	75.91%	61.28%	77.31%	23.97%

Candel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CADL Candel Therapeutics	2.5299 of 5 stars	$10.59 flat	$18.57 +75.4%	+75.9%	$775.93M	N/A	N/A	60	News Coverage Upcoming Earnings Analyst Upgrade
BEAM Beam Therapeutics	2.0235 of 5 stars	$25.91 +1.5%	$46.85 +80.8%	+56.0%	$2.63B	$139.74M	N/A	510	Earnings Report Analyst Downgrade
KOD Kodiak Sciences	1.4908 of 5 stars	$39.83 -4.2%	$48.14 +20.9%	+474.3%	$2.60B	N/A	N/A	90	Upcoming Earnings
IMNM Immunome	3.226 of 5 stars	$23.01 +1.1%	$33.17 +44.1%	+158.3%	$2.58B	$6.94M	N/A	40	Upcoming Earnings Insider Trade
RARE Ultragenyx Pharmaceutical	3.7334 of 5 stars	$25.02 +0.4%	$57.94 +131.6%	-5.9%	$2.45B	$673M	N/A	1,371	Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CADL) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Candel Therapeutics (CADL) Competitors

CADL vs. BEAM, KOD, IMNM, RARE, and NRIX

How does Candel Therapeutics compare to Beam Therapeutics?

Summary

How does Candel Therapeutics compare to Kodiak Sciences?

Summary

How does Candel Therapeutics compare to Immunome?

Summary

How does Candel Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does Candel Therapeutics compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Candel Therapeutics (CADL) Competitors

CADL vs. BEAM, KOD, IMNM, RARE, and NRIX

How does Candel Therapeutics compare to Beam Therapeutics?

Do insiders and institutionals hold more shares of BEAM or CADL?

Which has preferable valuation & earnings, BEAM or CADL?

Does the media prefer BEAM or CADL?

Which has more risk and volatility, BEAM or CADL?

Is BEAM or CADL more profitable?

Do analysts rate BEAM or CADL?

Summary

How does Candel Therapeutics compare to Kodiak Sciences?

Which has more volatility and risk, KOD or CADL?

Does the media refer more to KOD or CADL?

Which has higher valuation & earnings, KOD or CADL?

Do analysts rate KOD or CADL?

Is KOD or CADL more profitable?

Do insiders & institutionals have more ownership in KOD or CADL?

Summary

How does Candel Therapeutics compare to Immunome?

Do insiders and institutionals have more ownership in CADL or IMNM?

Is CADL or IMNM more profitable?

Which has better earnings and valuation, CADL or IMNM?

Does the media favor CADL or IMNM?

Which has more volatility & risk, CADL or IMNM?

Do analysts recommend CADL or IMNM?

Summary

How does Candel Therapeutics compare to Ultragenyx Pharmaceutical?

Which has higher earnings & valuation, CADL or RARE?

Is CADL or RARE more profitable?

Do insiders & institutionals believe in CADL or RARE?

Which has more volatility & risk, CADL or RARE?

Does the media prefer CADL or RARE?

Do analysts prefer CADL or RARE?

Summary

How does Candel Therapeutics compare to Nurix Therapeutics?

Do insiders & institutionals have more ownership in NRIX or CADL?

Is NRIX or CADL more profitable?

Does the media refer more to NRIX or CADL?

Which has more volatility and risk, NRIX or CADL?

Which has higher earnings and valuation, NRIX or CADL?

Do analysts recommend NRIX or CADL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools